Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy

BACKGROUND: The optimal timing to initiate bevacizumab (BV) therapy for recurrent glioblastoma (GBM) is currently unclear. To address this issue, we examined progression-free survival (PFS) and survival time (ST) in a large retrospective cohort of GBM patients treated with BV at different recurrence...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Piccioni, David E., Selfridge, Julia, Mody, Reema R., Chowdhury, Reshmi, Li, Sichen, Lalezari, Shadi, Wawrzynski, James, Quan, Jennifer, Zurayk, Mira, Chou, Arthur P., Sanchez, Desiree E., Liau, Linda M., Ellingson, Benjamin M., Pope, Whitney B., Nghiemphu, Phioanh L., Green, Richard M., Wang, He-jing, Yong, William H., Elashoff, Robert, Cloughesy, Timothy F., Lai, Albert
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2014
Gaiak:
Clinical Investigations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4022228/
https://ncbi.nlm.nih.gov/pubmed/24627236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou028
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak